Publications

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.

Mayne KJ. et al, (2024), Clin J Am Soc Nephrol

Effect of Fenofibrate on Progression of Diabetic Retinopathy.

Preiss D. et al, (2024), NEJM Evid

Association of daily steps with incident non-alcoholic fatty liver disease: Evidence from the UK Biobank cohort

Fulda ES. et al, (2024)

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.

Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk None. and Cholesterol Treatment Trialists’ (CTT) Collaboration None., (2024), Lancet Diabetes Endocrinol, 12, 306 - 319

Design, recruitment and baseline characteristics of the LENS trial.

LENS Collaborative Group None., (2024), Diabetic medicine : a journal of the British Diabetic Association

Diabetic Retinopathy and Quality of Life: A Systematic Review and Meta-Analysis.

Zayed MG. et al, (2024), JAMA Ophthalmol

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.

EMPA-KIDNEY Collaborative Group None., (2024), The lancet. Diabetes & endocrinology, 12, 51 - 60

Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease

Mayne K. et al, (2023), Journal of the American Society of Nephrology

Quality of care for secondary cardiovascular disease prevention in 2009- 2017: population-wide cohort study of antiplatelet therapy use in Scotland

PREISS D. et al, (2023), BMJ Quality and Safety

Intima-media thickness at the near or far wall of the common carotid artery in cardiovascular risk assessment.

Seekircher L. et al, (2023), Eur Heart J Open, 3

Late-Breaking Science Abstracts and Featured Science Abstracts From the American Heart Association's Scientific Sessions 2022 and Late-Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2022.

(2022), Circulation, 146, e569 - e605

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.

Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet, 400, 1788 - 1801